Clinical effectiveness of docetaxel for castration‐sensitive prostate cancer in a real‐world population‐based analysis

Background Adding docetaxel to androgen deprivation therapy (ADT) for the treatment of metastatic castration‐sensitive prostate cancer (mCSPC) has known efficacy, with an overall survival benefit in Phase III clinical trials. The effectiveness of docetaxel with ADT in the general patient population...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Prostate 2019-02, Vol.79 (3), p.281-287
Hauptverfasser:	Lavoie, Jean‐Michel, Zou, Kevin, Khalaf, Daniel, Eigl, Bernhard J., Kollmannsberger, Christian K., Vergidis, Joanna, Noonan, Krista, Zulfiqar, Muhammad, Finch, Daygen, Chi, Kim N.
Format:	Artikel
Sprache:	eng
Schlagworte:	Bone cancer Castration clinical effectiveness Clinical trials docetaxel Metastases Neutropenia Patients Prostate cancer Survival Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!